Tianjin Medical University General Hospital
Clinical trials sponsored by Tianjin Medical University General Hospital, explained in plain language.
-
Promising drug may halt devastating NMOSD attacks faster
Disease control OngoingThis study tests whether eculizumab can help people having a sudden attack of NMOSD, a rare autoimmune disease that damages the nerves in the eyes and spine. The drug works by blocking part of the immune system to stop nerve injury. About 110 adults who test positive for a specif…
Phase: PHASE2 • Sponsor: Tianjin Medical University General Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for MOGAD patients: drug aims to stop relapses
Disease control OngoingThis study tests whether the drug tocilizumab can safely prevent or delay relapses in people with MOGAD, a rare autoimmune disease that attacks the nervous system. About 102 participants aged 12 and older who have had at least one relapse in the past year will receive either toci…
Phase: PHASE2, PHASE3 • Sponsor: Tianjin Medical University General Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Promising NMOSD attack treatment trial pulled before it began
Disease control TerminatedThis study aimed to test the drug eculizumab for people having an acute attack of neuromyelitis optica spectrum disorder (NMOSD), a condition where the immune system attacks the central nervous system. The trial planned to give four weekly doses of eculizumab alongside standard s…
Phase: PHASE2 • Sponsor: Tianjin Medical University General Hospital • Aim: Disease control
Last updated Jun 26, 2026 16:48 UTC